Get the Stockscreener App
54.99
3.27%
1.74
After Hours:
54.99
Korro Bio Inc stock is traded at $54.99, with a volume of 35,074.
It is up +3.27% in the last 24 hours and down -19.31% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$53.25
Open:
$54.34
24h Volume:
35,074
Relative Volume:
0.30
Market Cap:
$503.64M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-82.84M
1W Performance:
+17.00%
1M Performance:
-19.31%
6M Performance:
+12.57%
1Y Performance:
+46.64%
1-Day Range:
$50.92
$55.20
1-Week Range:
$47.41
$56.69
52-Week Range:
$30.00
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
54.99 | 503.64M | 0 | -81.17M | -82.84M | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio, Inc Receives Approval from the Australian Bellberry Human Research Ethics Committee and Clearance from the Australian Therapeutic Goods Administration to Initiate A Phase 1/2A Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency - Marketscreener.com
Korro Bio's SWOT analysis: RNA editing stock poised for growth amid AATD treatment race - Investing.com
HC Wainwright Reaffirms Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Korro Bio (NASDAQ:KRRO) Trading 9.3% HigherHere's What Happened - MarketBeat
Korro Bio (NASDAQ:KRRO) Receives Buy Rating from HC Wainwright - MarketBeat
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro Bio CEO to Present at Major Healthcare Conferences in December | KRRO Stock News - StockTitan
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Korro Bio Gains Approval for Phase 1/2a AATD Treatment Trial, Shows Strong Preclinical Data | KRRO Stock News - StockTitan
Jones Trading bullish on Korro Bio stock amid RNA editing and AATD prospects - Investing.com
Jones Trading Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - MSN
Korro Bio FY2024 EPS Forecast Increased by HC Wainwright - MarketBeat
William Blair Has Positive View of Korro Bio FY2024 Earnings - MarketBeat
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Eventide Asset Management's Strategic Reduction in Korro Bio Inc Holdings - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition of Korro Bio Inc Shares - GuruFocus.com
Korro to Present at the Jefferies London Healthcare Conference - The Manila Times
Korro Bio to Present RNA-Editing Breakthroughs at Jefferies London Healthcare Conference | KRRO Stock News - StockTitan
Korro Bio’s Progress and Financial Updates - TipRanks
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
William Blair Reiterates "Outperform" Rating for Korro Bio (NASDAQ:KRRO) - MarketBeat
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
FMR LLC Reduces Stake in Korro Bio Inc - GuruFocus.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock - Investing.com
Korro Bio CFO Vineet Agarwal sells $56,000 in stock By Investing.com - Investing.com UK
Korro Bio Partners with Novo Nordisk, Reports $169M Cash Position Despite Widening Losses | KRRO Stock News - StockTitan
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
Korro Bio (NASDAQ:KRRO) Stock Price Up 10.9%Here's What Happened - MarketBeat
Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD - BioWorld Online
Korro Bio (NASDAQ:KRRO) Shares Gap DownHere's Why - MarketBeat
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board - The Manila Times
Korro Bio, Inc. Announces Submission to Bellberry HREC for Phase 1/2 Clinical Study of KRRO-110 for AATD - Marketscreener.com
Korro Bio (NASDAQ:KRRO) Trading Down 5.1%Time to Sell? - MarketBeat
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap - Investing.com India
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap By Investing.com - Investing.com South Africa
Korro Bio (NASDAQ:KRRO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Korro Bio (NASDAQ:KRRO) Coverage Initiated at Raymond James - Defense World
RBC lifts Korro Bio stock target on positive RNA editing outlook - Investing.com Australia
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation - MSN
Korro Bio price target raised to $105 from $95 at RBC Capital - TipRanks
RBC lifts Korro Bio stock target on positive RNA editing outlook By Investing.com - Investing.com South Africa
Royal Bank of Canada Boosts Korro Bio (NASDAQ:KRRO) Price Target to $105.00 - MarketBeat
Korro Bio initiated with a Strong Buy at Raymond James - TipRanks
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. - Investor's Business Daily
Korro bio CFO Vineet Agarwal sells $799,526 in stock - Investing.com India
Insider Selling: Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells 10,216 Shares of Stock - MarketBeat
Korro bio CFO Vineet Agarwal sells $799,526 in stock By Investing.com - Investing.com Australia
Korro Bio shares target lifted, buy rating on RNA editing potential - Investing.com
Korro Bio (NASDAQ:KRRO) Trading Down 4.1%Should You Sell? - MarketBeat
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):